Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 10, Issue 6, Pages e004582
Publisher
BMJ
Online
2022-06-20
DOI
10.1136/jitc-2022-004582
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
- (2021) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
- (2021) Irina Khononov et al. Journal for ImmunoTherapy of Cancer
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
- (2021) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- TMB in NSCLC: A Broken Dream?
- (2021) Sara Bravaccini et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
- (2021) Mohamed Eltahir et al. Cancers
- Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
- (2021) Roy S. Herbst et al. Journal of Thoracic Oncology
- Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma
- (2020) Benjamin P. Fairfax et al. NATURE MEDICINE
- Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
- (2020) Manuela Tiako Meyo et al. Cancers
- Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
- (2020) Kurt A. Schalper et al. NATURE MEDICINE
- Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort
- (2020) Kyle G Mitchell et al. Journal for ImmunoTherapy of Cancer
- Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
- (2020) Aleksandra Filipovic et al. Frontiers in Cell and Developmental Biology
- Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
- (2020) Michael A. Gillette et al. CELL
- Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
- (2020) Rilan Bai et al. Biomarker Research
- The Gene Ontology resource: enriching a GOld mine
- (2020) et al. NUCLEIC ACIDS RESEARCH
- The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets
- (2020) Damian Szklarczyk et al. NUCLEIC ACIDS RESEARCH
- Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab
- (2019) Jun Oyanagi et al. LUNG CANCER
- Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
- (2019) Deborah B Doroshow et al. CLINICAL CANCER RESEARCH
- Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
- (2019) Sanjeevani Arora et al. ADVANCES IN THERAPY
- The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials
- (2019) Yangyang Xu et al. Translational Lung Cancer Research
- Adenosine Metabolism: Emerging Concepts for Cancer Therapy
- (2019) Detlev Boison et al. CANCER CELL
- Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment
- (2018) Hirotake Tsukamoto et al. CANCER RESEARCH
- Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma
- (2018) Yiwei Liu et al. Clinical Lung Cancer
- Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer
- (2018) A. Pabani et al. Current Oncology
- Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
- (2018) Noam Auslander et al. NATURE MEDICINE
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- The Perseus computational platform for comprehensive analysis of (prote)omics data
- (2016) Stefka Tyanova et al. NATURE METHODS
- Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects
- (2016) Yuval Shaked Nature Reviews Clinical Oncology
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- CXCL9: evidence and contradictions for its role in tumor progression
- (2016) Qiang Ding et al. Cancer Medicine
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Tissue-based map of the human proteome
- (2015) M. Uhlen et al. SCIENCE
- Visual account of protein investment in cellular functions
- (2014) W. Liebermeister et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The emerging role of CXCL10 in cancer (Review)
- (2011) MINGLI LIU et al. Oncology Letters
- ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
- (2010) Matthew D. Wilkerson et al. BIOINFORMATICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now